CA2229143A1 - Reagents and methods useful for controlling the translation of hepatitis gbv proteins - Google Patents

Reagents and methods useful for controlling the translation of hepatitis gbv proteins Download PDF

Info

Publication number
CA2229143A1
CA2229143A1 CA002229143A CA2229143A CA2229143A1 CA 2229143 A1 CA2229143 A1 CA 2229143A1 CA 002229143 A CA002229143 A CA 002229143A CA 2229143 A CA2229143 A CA 2229143A CA 2229143 A1 CA2229143 A1 CA 2229143A1
Authority
CA
Canada
Prior art keywords
nucleic acid
gbv
sequence
hgbv
cat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002229143A
Other languages
English (en)
French (fr)
Inventor
John N. Simons
Suresh M. Desai
Isa K. Mushahwar
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/580,038 external-priority patent/US5807670A/en
Application filed by Individual filed Critical Individual
Publication of CA2229143A1 publication Critical patent/CA2229143A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3181—Peptide nucleic acid, PNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/55—Vectors comprising a special translation-regulating system from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
CA002229143A 1995-08-14 1996-08-14 Reagents and methods useful for controlling the translation of hepatitis gbv proteins Abandoned CA2229143A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US226595P 1995-08-14 1995-08-14
US08/580,038 US5807670A (en) 1995-08-14 1995-12-21 Detection of hepatitis GB virus genotypes
US08/580,038 1995-12-21
US60/002,265 1995-12-21
US08/639,857 1996-04-19
US08/639,857 US5955318A (en) 1995-08-14 1996-04-19 Reagents and methods useful for controlling the translation of hepatitis GBV proteins

Publications (1)

Publication Number Publication Date
CA2229143A1 true CA2229143A1 (en) 1997-02-27

Family

ID=27357120

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002229143A Abandoned CA2229143A1 (en) 1995-08-14 1996-08-14 Reagents and methods useful for controlling the translation of hepatitis gbv proteins

Country Status (5)

Country Link
US (1) US5955318A (enExample)
EP (1) EP0845042A1 (enExample)
JP (1) JP2001519642A (enExample)
CA (1) CA2229143A1 (enExample)
WO (1) WO1997007224A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10002027A1 (de) * 2000-01-19 2001-07-26 Tenovis Gmbh & Co Kg Vorrichtung zur direkten Herstellung von Telekommunikationsverbindungen von einer TK-Anlage ins Mobilfunknetz
US20030224353A1 (en) * 2001-10-16 2003-12-04 Stein David A. Antisense antiviral agent and method for treating ssRNA viral infection
US6828105B2 (en) * 2001-10-16 2004-12-07 Avi Biopharma, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
WO2003046138A2 (en) * 2001-11-26 2003-06-05 Duke University Genetically stable expression vector
EP1668145A4 (en) * 2003-08-07 2010-03-10 Avi Biopharma Inc SENSE ANTIVIRUS COMPOUND AND METHOD FOR TREATING SSRNA VIRUS INFECTION
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US8129352B2 (en) 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
US8357664B2 (en) 2004-10-26 2013-01-22 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
US7524829B2 (en) 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US8524676B2 (en) * 2005-09-08 2013-09-03 Sarepta Therapeutics, Inc. Method for treating enterovirus or rhinovirus infection using antisense antiviral compounds
WO2007030576A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
CA2645024C (en) * 2006-03-29 2011-11-08 Graphic Packaging International, Inc. Carrier packages and methods of erecting carrier packages
ES2645410T3 (es) * 2006-05-10 2017-12-05 Sarepta Therapeutics, Inc. Análogos de oligonucleótidos que tienen enlaces intersubunitarios catiónicos
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
US20100035248A1 (en) * 2007-06-15 2010-02-11 Rastislav Levicky Surface-based nucleic acid assays employing morpholinos
WO2010080554A1 (en) 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
WO2011060320A1 (en) 2009-11-13 2011-05-19 Avi Biopharma, Inc. Antisense antiviral compound and method for treating influenza viral infection
EP2576574A2 (en) 2010-05-28 2013-04-10 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
CN108864192A (zh) 2011-11-18 2018-11-23 萨勒普塔医疗公司 功能改性的寡核苷酸及其亚单元
WO2014084354A1 (ja) * 2012-11-29 2014-06-05 国立大学法人岐阜大学 Ｒｎａ干渉剤、その製造方法及びその利用
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743535A (en) * 1984-11-07 1988-05-10 Miles Inc. Hybridization assay employing labeled probe and anti-hybrid
US4876187A (en) * 1985-12-05 1989-10-24 Meiogenics, Inc. Nucleic acid compositions with scissile linkage useful for detecting nucleic acid sequences
IE62868B1 (en) * 1987-11-18 1995-03-08 Chiron Corp Hepatitis C virus
JPH04501203A (ja) * 1988-07-06 1992-03-05 ジェネラブズ　インコーポレイティド 後―輸血性，非―ａ，非―ｂ型肝炎ウィルス及び抗原
JP2696116B2 (ja) * 1988-09-30 1998-01-14 財団法人阪大微生物病研究会 非ａ非ｂ肝炎患者の血清と抗原抗体反応するペプチド、及び該ペプチドをコードするｄｎａ
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
ES2111589T3 (es) * 1991-08-27 1998-03-16 Hoffmann La Roche Metodos y reactivos para la deteccion de la hepatitis c.
US5576302A (en) * 1991-10-15 1996-11-19 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity
WO1994018217A1 (en) * 1993-02-03 1994-08-18 Abbott Laboratories Non-a, non-b, non-c, non-d, non-e hepatitis reagents and methods for their use
JP4637972B2 (ja) * 1992-09-28 2011-02-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｈｃｖタンパク質の翻訳を制御するための方法および組成物
US5663279A (en) * 1993-08-24 1997-09-02 Akzo Nobel Nv Ophthalmic lenses
AU2594195A (en) * 1994-05-20 1995-12-18 Genelabs Technologies, Inc. Detection of viral antigens coded by reverse-reading frames
AU2549195A (en) * 1994-05-20 1995-12-18 Genelabs Technologies, Inc. Non-A/non-B/non-C/non-D/non-E hepatitis agents and molecular cloning thereof
JPH10503642A (ja) * 1994-05-20 1998-04-07 ジェネラブス テクノロジーズ， インコーポレイテッド Ｇ型肝炎ウイルスおよびその分子クローニング

Also Published As

Publication number Publication date
JP2001519642A (ja) 2001-10-23
WO1997007224A1 (en) 1997-02-27
EP0845042A1 (en) 1998-06-03
US5955318A (en) 1999-09-21

Similar Documents

Publication Publication Date Title
CA2229143A1 (en) Reagents and methods useful for controlling the translation of hepatitis gbv proteins
Lieber et al. Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library
Spandau et al. Trans-activation of viral enhancers by the hepatitis B virus X protein
JP4191786B2 (ja) Ｈｃｖタンパク質の翻訳を制御するための方法および組成物
Fallows et al. Mutations in the epsilon sequences of human hepatitis B virus affect both RNA encapsidation and reverse transcription
US6043077A (en) Hepatitis C virus ribozymes
Been et al. Self‐cleaving ribozymes of hepatitis delta virus RNA
Brady et al. Identification of p40x-responsive regulatory sequences within the human T-cell leukemia virus type I long terminal repeat
Fraser et al. Assay for movement of Lepidopteran transposon IFP2 in insect cells using a baculovirus genome as a target DNA
Lenhoff et al. Coordinate regulation of replication and virus assembly by the large envelope protein of an avian hepadnavirus
Nassal et al. Translational inactivation of RNA function: discrimination against a subset of genomic transcripts during HBV nucleocapsid assembly
US6107027A (en) Ribozymes for treating hepatitis C
US5922857A (en) Methods and compositions for controlling translation of HCV proteins
US5686120A (en) Pre-mRNA processing enhancer and method for intron-independent gene expression
Rieger et al. Distinct requirements for primary sequence in the 5′-and 3′-part of a bulge in the hepatitis B virus RNA encapsidation signal revealed by a combined in vivo selection/in vitro amplification system
WO1998049195A1 (en) Corona virus-like particles as tools for vaccination and therapy
CN103328004A (zh) 感染性戊型肝炎病毒基因型3的重组体
Weber et al. A cDNA clone of tomato mosaic virus is infectious in plants
US5989886A (en) Method for the inhibition and prevention of viral replication using fusions of a virus protein and a destructive enzyme
Aloni et al. Attenuation May Regulate Gene Expression in Animal Viruses and Cell
JP2023517581A (ja) ＣＰＲ富化メタゲノム由来のＣＲＩＳＰＲ－Ｃａｓヌクレアーゼ
CN1207775A (zh) 条件复制型病毒载体及其用法
Taylor Human hepatitis delta virus
Simons et al. Efficient analysis of nonviable poliovirus capsid mutants
CA2158427C (en) Methods and compositions for controlling translation of hcv proteins

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued